Immunovant, Inc. (IMVT): who owns it and who trades it
As of Nov 16, 2026, IMVT insiders reported 63 open-market sales worth $16.6M and 1 purchase worth $350M in the last 12 months, with 9% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew J. Fromkin (Director), with $8M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Immunovant
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IMVT
226 funds and institutions reported IMVT shares worth $4.4B at the end of Q2 2026, about 56% of the company. The largest holder is FMR LLC (Fidelity) with 7.9%.
Funds and institutions (13F) 56%Everyone else 44%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 16.19M | 7.88% | $624M | -4% |
| Deep Track Capital, LP | 9.34M | 4.55% | $360M | -19% |
| BlackRock, Inc. | 7.18M | 3.50% | $277M | +9% |
| Farallon Capital Management, L.l.c. | 5.80M | 2.83% | $224M | +275% |
| Baker Bros. Advisors LP | 5.44M | 2.65% | $209M | -0% |
| State Street Corp | 4.62M | 2.25% | $178M | +2% |
| Morgan Stanley | 4.53M | 2.21% | $175M | +17% |
| TCG Crossover Management, LLC | 4.46M | 2.17% | $172M | No change |
| Vanguard Portfolio Management LLC | 3.91M | 1.90% | $151M | +6% |
| Vanguard Capital Management LLC | 3.64M | 1.77% | $140M | +1% |
| California State Teachers Retirement System | 3.53M | 1.72% | $91.7M | +3647% |
| Jennison Associates LLC | 3.31M | 1.61% | $128M | +4% |
| Rtw Investments, LP | 3.18M | 1.55% | $122M | No change |
| Two Seas Capital LP | 3.15M | 1.53% | $121M | -2% |
| ADAR1 Capital Management, LLC | 2.33M | 1.14% | $89.8M | -13% |
| Geode Capital Management, LLC | 2.23M | 1.09% | $86.1M | +7% |
| T. Rowe Price Investment Management, Inc. | 2.22M | 1.08% | $85.6M | -38% |
| Woodline Partners LP | 1.98M | 0.96% | $76.1M | No change |
| T. Rowe Price Associates | 1.83M | 0.89% | $70.5M | +439% |
| Goldman Sachs Group Inc | 1.75M | 0.85% | $67.5M | -2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IMVT insiders reported $350M of open-market purchases and $16.6M of sales. 9% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Atul Pande | Director | Sale plan | 3,000 | $36.00 | $108K | Form 4 |
| Oct 28, 2026 | Tiago Girao | CFO | Sale | 6,606 | $28.50 | $188K | Form 4 |
| Oct 21, 2026 | Jay S Stout | Chief Technology Officer | Sale | 2,595 | $28.94 | $75.1K | Form 4 |
| Oct 7, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 2,241 | $32.06 | $71.8K | Form 4 |
| Oct 7, 2026 | Jay S Stout | Chief Technology Officer | Sale | 2,213 | $32.06 | $70.9K | Form 4 |
| Oct 7, 2026 | Jay S Stout | Chief Technology Officer | Sale | 1,596 | $32.06 | $51.2K | Form 4 |
| Oct 7, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 1,327 | $32.06 | $42.5K | Form 4 |
| Oct 2, 2026 | Eric Venker | CEO | Sale | 3,506 | $34.11 | $120K | Form 4 |
| Sep 23, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 2,846 | $36.36 | $103K | Form 4 |
| Aug 28, 2026 | Atul Pande | Director | Sale plan | 1,500 | $43.27 | $64.9K | Form 4 |
| Aug 20, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 3,056 | $44.16 | $135K | Form 4 |
| Jul 24, 2026 | Atul Pande | Director | Sale plan | 1,500 | $39.80 | $59.7K | Form 4 |
| Jul 23, 2026 | Tiago Girao | CFO | Sale | 6,798 | $38.69 | $263K | Form 4 |
| Jul 23, 2026 | Jay S Stout | Chief Technology Officer | Sale | 2,857 | $38.69 | $111K | Form 4 |
| Jul 8, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 106 | $39.99 | $4.2K | Form 4 |
| Jul 8, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 1,930 | $39.53 | $76.3K | Form 4 |
| Jul 8, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 63 | $39.99 | $2.5K | Form 4 |
| Jul 8, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 1,143 | $39.53 | $45.2K | Form 4 |
| Jul 8, 2026 | Jay S Stout | Chief Technology Officer | Sale | 1,399 | $39.53 | $55.3K | Form 4 |
| Jul 8, 2026 | Jay S Stout | Chief Technology Officer | Sale | 77 | $39.99 | $3.1K | Form 4 |
| Jul 8, 2026 | Jay S Stout | Chief Technology Officer | Sale | 105 | $39.99 | $4.2K | Form 4 |
| Jul 8, 2026 | Jay S Stout | Chief Technology Officer | Sale | 1,906 | $39.53 | $75.3K | Form 4 |
| Jul 2, 2026 | Eric Venker | CEO | Sale | 3,092 | $38.48 | $119K | Form 4 |
| Jun 26, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 14,748 | $38.18 | $563K | Form 4 |
| Jun 26, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 2,966 | $38.95 | $116K | Form 4 |
| Jun 26, 2026 | Jay S Stout | Chief Technology Officer | Sale | 6,723 | $38.94 | $262K | Form 4 |
| Jun 26, 2026 | Jay S Stout | Chief Technology Officer | Sale | 33,277 | $38.18 | $1.3M | Form 4 |
| Jun 26, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 2,842 | $38.96 | $111K | Form 4 |
| Jun 26, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 14,982 | $38.19 | $572K | Form 4 |
| Jun 26, 2026 | Tiago Girao | CFO | Sale | 10,000 | $38.46 | $385K | Form 4 |
| Jun 26, 2026 | Atul Pande | Director | Sale plan | 1,500 | $38.01 | $57K | Form 4 |
| Jun 18, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 2,634 | $35.39 | $93.2K | Form 4 |
| Jun 15, 2026 | Atul Pande | Director | Sale plan | 1,500 | $34.02 | $51K | Form 4 |
| May 28, 2026 | Andrew J. Fromkin | Director | Sale | 210,468 | $33.56 | $7.1M | Form 4 |
| May 28, 2026 | Andrew J. Fromkin | Director | Sale | 11,483 | $32.64 | $375K | Form 4 |
| May 20, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 249 | $30.41 | $7.6K | Form 4 |
| May 20, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 1,698 | $32.95 | $55.9K | Form 4 |
| May 20, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 1,168 | $32.15 | $37.6K | Form 4 |
| May 20, 2026 | Atul Pande | Director | Sale plan | 6,000 | $32.00 | $192K | Form 4 |
| May 1, 2026 | Robert Graham Susman | Director | Sale plan | 2,502 | $27.17 | $68K | Form 4 |
| Apr 23, 2026 | Tiago Girao | CFO | Sale | 25,760 | $29.62 | $763K | Form 4 |
| Apr 23, 2026 | Jay S Stout | Chief Technology Officer | Sale | 2,754 | $29.62 | $81.6K | Form 4 |
| Apr 8, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 5,165 | $24.83 | $128K | Form 4 |
| Apr 8, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 8,722 | $24.83 | $217K | Form 4 |
| Apr 8, 2026 | Jay S Stout | Chief Technology Officer | Sale | 8,614 | $24.83 | $214K | Form 4 |
| Apr 8, 2026 | Jay S Stout | Chief Technology Officer | Sale | 1,518 | $24.83 | $37.7K | Form 4 |
| Apr 2, 2026 | Eric Venker | CEO | Sale | 1,409 | $24.60 | $34.7K | Form 4 |
| Apr 2, 2026 | Eric Venker | CEO | Sale | 12,820 | $24.04 | $308K | Form 4 |
| Mar 18, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sale | 2,877 | $24.97 | $71.8K | Form 4 |
| Feb 25, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 942 | $28.90 | $27.2K | Form 4 |
| Feb 25, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 859 | $28.16 | $24.2K | Form 4 |
| Feb 25, 2026 | Melanie Gloria | Chief Operating Officer | Sale | 1,437 | $26.98 | $38.8K | Form 4 |
| Jan 21, 2026 | Jay S Stout | Chief Technology Officer | Sale | 1,977 | $26.03 | $51.5K | Form 4 |
| Jan 7, 2026 | Jay S Stout | Chief Technology Officer | Sale | 1,148 | $26.51 | $30.4K | Form 4 |
| Jan 7, 2026 | Jay S Stout | Chief Technology Officer | Sale | 55 | $26.92 | $1.5K | Form 4 |
| Dec 18, 2025 | Tuyl Christopher Van | Chief Legal Officer | Sale | 2,284 | $27.38 | $62.5K | Form 4 |
| Dec 18, 2025 | Tuyl Christopher Van | Chief Legal Officer | Sale | 8,529 | $26.78 | $228K | Form 4 |
| Dec 12, 2025 | Roivant Sciences Ltd. | Director | Purchase | 16.67M | $21.00 | $350M | Form 4 |
| Dec 1, 2025 | Andrew J. Fromkin | Director | Sale plan | 19,351 | $23.14 | $448K | Form 4 |
| Dec 1, 2025 | Andrew J. Fromkin | Director | Sale plan | 2,898 | $23.95 | $69.4K | Form 4 |
| Dec 1, 2025 | Douglas J. Hughes | Director | Sale plan | 13,091 | $23.14 | $303K | Form 4 |
| Dec 1, 2025 | Douglas J. Hughes | Director | Sale plan | 1,909 | $23.96 | $45.7K | Form 4 |
| Nov 20, 2025 | Melanie Gloria | Chief Operating Officer | Sale | 10,251 | $23.54 | $241K | Form 4 |
| Nov 20, 2025 | Melanie Gloria | Chief Operating Officer | Sale | 2,375 | $23.97 | $56.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10% owner | $350M | – | Dec 12, 2025 |
| Andrew J. Fromkin | Director | – | $8M | May 28, 2026 |
| Jay S Stout | Chief Technology Officer | – | $2.4M | Oct 21, 2026 |
| Melanie Gloria | Chief Operating Officer | – | $1.7M | Oct 7, 2026 |
| Tiago Girao | Chief Financial Officer | – | $1.6M | Oct 28, 2026 |
| Tuyl Christopher Van | Chief Legal Officer | – | $1.5M | Oct 7, 2026 |
| Eric Venker | Chief Executive Officer, Director | – | $581K | Oct 2, 2026 |
| Atul Pande | Director | – | $533K | Nov 11, 2026 |
| Douglas J. Hughes | Director | – | $349K | Dec 1, 2025 |
| Robert Graham Susman | Director | – | $68K | May 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMVT short interest
Moderate short interest. 9.0% of IMVT shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 18.55M IMVT shares were sold short, 9.0% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 15.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 18.55M | 8.98% | +2% | 1.22M | 15.3 |
| Oct 15, 2026 | 18.27M | 8.85% | +5% | 1.48M | 12.3 |
| Sep 30, 2026 | 17.42M | 8.43% | +1% | 1.81M | 9.6 |
| Sep 15, 2026 | 17.25M | 8.35% | +9% | 1.20M | 14.3 |
| Aug 31, 2026 | 15.78M | 7.64% | -7% | 1.12M | 14.1 |
| Aug 14, 2026 | 16.98M | 8.22% | +4% | 1.13M | 15.1 |
| Jul 31, 2026 | 16.38M | 7.98% | -8% | 884,266 | 18.5 |
| Jul 15, 2026 | 17.76M | 8.65% | -1% | 1.06M | 16.7 |
| Jun 30, 2026 | 17.99M | 8.76% | -7% | 2.09M | 8.6 |
| Jun 15, 2026 | 19.34M | 9.42% | +1% | 1.37M | 14.1 |
| May 29, 2026 | 19.21M | 9.36% | -6% | 3.85M | 5.0 |
| May 15, 2026 | 20.37M | 9.92% | +10% | 1.24M | 16.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Immunovant company events
Immunovant filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Sep 3, 2026VoteReported shareholder vote results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 20, 2026ResultsReleased financial results. Filing
- Feb 6, 2026ResultsReleased financial results. Filing
- Dec 12, 2025AnnouncementImmunovant, Inc. entered into an underwriting agreement with Leerink Partners LLC, relating to the issuance and sale in an underwritten offering by the Company of 26.2 million shares of the Company’s common stock, par value $0.0001 per share, at an offering price of $21.00 per share. Filing
- Dec 11, 2025AnnouncementImmunovant, Inc. announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to the Company of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by the Company in connection with the transaction. Filing
- Nov 21, 2025LeadershipMichael Geffner, M.D., M.B.A., ceased serving as the Chief Medical Officer of Immunovant, Inc., effective November 21, 2025, in connection with the Company’s restructuring of its R&D leadership structure under the Company’s Chief Executive Officer, Eric Venker, M.D., PharmD. The Company has entered… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Immunovant financials
Famous investors that hold IMVT
4 of the 50 well-known investors we track reported holding IMVT in their latest 13F filing. The largest position is Jim Simons's, worth $26.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 779,500 | $26.3M | 0.0% | +7% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 545,730 | $18.4M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 256,789 | $8.7M | 0.0% | -22% |
| David Einhorn · Greenlight Capital (DME) | Q3 2026 | 70,140 | $2.4M | 0.1% | -25% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Immunovant, Inc. (IMVT) stock
Who owns the most IMVT stock?
The largest reported owner of Immunovant, Inc. (IMVT) is FMR LLC (Fidelity), with 7.9% of the company. In total, 226 funds and institutions reported holding IMVT at the end of Q2 2026, together about 56% of the shares. See the largest owners.
Are IMVT insiders buying or selling?
In the last 12 months, IMVT insiders reported 1 open-market purchase worth $350M and 63 sales worth $16.6M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in IMVT?
As of Oct 30, 2026, 18.55M IMVT shares were sold short, 9.0% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 15.3 trading days (days to cover). See the history.
Which famous investors hold IMVT?
4 of the 50 well-known investors we track reported IMVT in their latest 13F filing, including Jim Simons, Ken Fisher, Israel Englander. The largest position is worth $26.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.